Abstract
Biomet is one of the five largest orthopedic implant manufacturers in the
world, with distribution in the U.S., Europe, Asia and a number of emerging
markets. Throughout its history, the company has also expanded into areas such
as sports medicine and dental medical devices. As of 2011, Biomet distributed
products in approximately 90 countries across the globe, earning revenues in
the billions. This report is a comprehensive overview of Biomet's business
activities with an in-depth analysis of the company's market share and
presence in global orthopedic large joint reconstructive device markets.
The information covered includes:
- An overview of the company history and current product divisions
- A summary of corporate financial metrics
- A review of recently approved products and the results of preliminary
clinical trials
- An in-depth review of the strengths, weaknesses opportunities and threats
(SWOT) to the company's orthopedic biomaterials divisions
- A detailed look at the market share and performance of each division in
various countries across the U.S., Europe and Asia. Whenever possible, market
share and division revenues are examined by individual country for each region
of the globe.
The key product areas covered in this report include:
- Hip Reconstruction
- Knee Reconstruction
The countries covered in this report include:
- U.S.
- Germany
- France
- U.K.
- Spain
- Italy
- Benelux
- Scandinavia
- Switzerland
- Austria
- Portugal
- Japan
- Australia
- South Korea
Table of Contents
TABLE OF CONTENTS
LIST OF FIGURES
LIST OF CHARTS
EXECUTIVE SUMMARY
- 1.1. REPORT OVERVIEW
- 1.2. CORPORATE OVERVIEW
- 1.3. CORPORATE REVENUE GROWTH BY BUSINESS UNIT
- 1.4. GLOBAL REVENUE BY REGION
- 1.5. GLOBAL MARKET SHARE BY MARKET SIZE
- 1.6. MARKET SHARE: ORTHOPEDIC BIOMATERIALS
RESEARCH METHODOLOGY
- 2.1. IDATA'S 9-STEP METHODOLOGY
- 2.1.1. Step 1: Project Initiation & Team Selection
- 2.1.2. Step 2: Prepare Data Systems and Perform Secondary Research
- 2.1.3. Step 3: Preparation for Interviews & Questionnaire Design
- 2.1.4. Step 4: Performing Primary Research
- 2.1.5. Step 5: Research Analysis: Establishing Baseline Estimates
- 2.1.6. Step 6: Market Forecast and Analysis
- 2.1.7. Step 7: Identify Strategic Opportunities
- 2.1.8. Step 8: Final Review and Market Release
- 2.1.9. Step 9: Customer Feedback and Market Monitoring
BIOMET COMPANY OVERVIEW
- 3.1. INTRODUCTION
- 3.2. COMPANY PROFILE
- 3.2.1. Business Units
- 3.2.1.1. Orthopedic Reconstruction
- 3.2.1.2. Orthopedic Trauma, Spine and Biologics
- 3.2.1.3. Sports Medicine
- 3.2.1.4. Craniomaxillofacial
- 3.2.1.5. Dental
- 3.3. GLOBAL REVENUES
- 3.3.1. Global Revenues by Division
- 3.3.2. Global Revenues by Geography
- 3.4. COMPANY HISTORY
- 3.5. COMPANY INFORMATION
- 3.5.1. Size
- 3.5.2. Office and Facility Locations
FINANCIAL METRICS
- 4.1. INCOME STATEMENT
- 4.2. BALANCE SHEET
- 4.2.1. Balance Sheet
- 4.2.2. Company Debt
PRODUCT PIPELINE
- 5.1. ORTHOPEDIC BIOMATERIALS
- 5.1.1. U.S. FDA Investigational Device Exemption (IDE)
- 5.1.1.1. Platelet Rich Plasmas for Tennis Elbow
- 5.1.2. U.S. FDA Phase 1 Trials
- 5.1.2.1. Bone Marrow Aspirate Concentration for Critical Limb Ischemia
- 5.1.3. U.S. FDA 510(k) Submissions
- 5.1.3.1. Bone Marrow Concentration System
- 5.1.4. European CE Mark Trials
- 5.1.4.1. ChonDux Trail Suspension
- 5.1.4.2. Fat Concentration System
SWOT ANALYSIS
- 6.1. ORTHOPEDIC BIOMATERIALS SWOT ANALYSIS
- 6.1.1. Strengths
- 6.1.1.1. Joint Reconstruction
- 6.1.1.2. History in Orthopedic Biologics
- 6.1.1.3. Market Leader in Cell Concentration Systems
- 6.1.1.4. Restructured Management
- 6.1.2. Weaknesses
- 6.1.2.1. Competition from Larger Competitors
- 6.1.2.2. Lack of Advanced Bone Graft Substitute Product
- 6.1.2.3. Partial Reliance on Distributors in the United States
- 6.1.2.4. High Debt Levels
- 6.1.2.5. Spine and Trauma Fixation Divisions
- 6.1.2.6. Staff Restructuring
- 6.1.3. Opportunities
- 6.1.3.1. Undeveloped Asian and Emerging Markets Presence
- 6.1.3.2. Underdeveloped Hyaluronic Acid Viscosupplementation Potential
- 6.1.3.3. Migration to Chinese Manufacturing
- 6.1.4. Threats
- 6.1.4.1. Cost Control
- 6.1.4.2. Medical Conservatism
- 6.1.4.3. Department of Justice Sanction
- 6.1.4.4. European Sovereign Debt Crisis of 2010 and Onward
- 6.1.4.5. Potential for Acquisition
ORTHOPEDIC BIOMATERIALS MARKET SHARE
- 7.1. MARKET INTRODUCTION
- 7.1.1. Bone Graft Substitutes
- 7.1.1.1. Introduction
- 7.1.1.2. Indications
- 7.1.1.3. Materials
- 7.1.2. Cell Concentration
- 7.1.2.1. Introduction
- 7.1.2.2. Platelet Rich Plasma
- 7.1.2.3. Bone Marrow Aspirate
- 7.1.3. Hyaluronic Acid Viscosupplementation
- 7.1.3.1. Introduction
- 7.1.3.2. Benefits of Viscosupplementation
- 7.1.3.3. Synovial Fluid
- 7.1.3.4. Three-Injection Cycle Products
- 7.1.3.5. Five-Injection Cycle Products
- 7.1.3.6. Single-Injection Cycle Products
- 7.2. KEY PRODUCTS
- 7.2.1. Bone Graft Substitutes
- 7.2.1.1. Allograft / DBM
- 7.2.1.2. Synthetic Bone Void Fillers
- 7.2.2. Hyaluronic Acid Viscosupplementation
- 7.2.3. Cell Concentration
- 7.3. MARKET SHARE AND REVENUE ANALYSIS
- 7.3.1. Bone Graft Substitutes
- 7.3.1.1. Global Market Share
- 7.3.1.2. United States Market Share
- 7.3.1.3. European Market Share by Country
- 7.3.1.4. International Market Share
- 7.3.2. Cell Concentration (Platelet and Bone Marrow)
- 7.3.2.1. Global
- 7.3.2.2. U.S. Market Share
- 7.3.2.3. European and International Market Share
- 7.3.3. Hyaluronic Acid Viscosupplementation
- 7.3.3.1. Global
- 7.3.3.2. U.S. Market Share
- 7.3.3.3. European Market Share
- 7.3.3.4. International Market Share
ABBREVIATIONS
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
